Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells

Circulation Journal

Volumn 74, Issue 3, 2010, Pages 567-571

  Matsumori, Akira ^a   Nishio, Ryosuke ^b   Nose, Yoshisuke ^c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c Japanese Red Cross Society   (Japan)

Author keywords

Calcium channel blockers; Cytokines; Immunology

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CONCANAVALIN A; CYTOKINE; DILTIAZEM; FICOLL; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NIFEDIPINE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ARTICLE; CELL ISOLATION; CELL STIMULATION; CYTOKINE PRODUCTION; DENSITY GRADIENT CENTRIFUGATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPERNATANT;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CYTOKINES; DILTIAZEM; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; NIFEDIPINE; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

EID: 77649217383     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0467     Document Type: Article

References (36)

1. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982; 307: 1618-1627.
2. Lee KS, Tsien RW. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 1983; 302: 790-794.
3. ++ antagonist-induced vasodilation: Intracellular actions. Circ Res 1983; 52: 137-142.
4. Walus KM, Fondacaro JD, Jacobson ED. Effects of calcium and its antagonists on the canine mesenteric circulation. Circ Res 1981; 48: 692-700.
5. Miwa Y, Masai H, Shimizu M. Differential effects of calcium-channel blockers on vascular endothelial function in patients with coronary spastic angina. Circ J 2009; 73: 713-717.
6. Kamide K, Yang J, Matayoshi T, Takiuchi S, Horio T, Yoshii M, et al. Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers. Circ J 2009; 73: 732-740.
7. Ogawa T, Komukai K, Ogawa K, Kosuga T, Nagoshi T, Minai K, et al. High incidence of repeat anginal attacks despite treatment with calcium-channel blockers in patients with coronary spastic angina. Circ J 2009; 73: 512-515.
8. Bacon KB, Westwick J, Camp RD. Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 1989; 165: 349-354.
9. Birx DL, Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984; 133: 2904-2909.
10. Tanizaki Y, Akagi K, Lee KN, Townley RG. Inhibitory effect of nifedipine and cromolyn sodium on skin reactions and 45Ca uptake and histamine release in rat mast cells induced by various stimulating agents. Int Arch Allergy Appl Immunol 1983; 72: 102-109.
11. Shen H, Wiederhold MD, Ou DW. The suppression of macrophage secretion by calcium blockers and adenosine. Immunopharmacol Immunotoxicol 1995; 17: 301-309.
12. Wright B, Zeidman I, Greig R, Poste G. Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. Cell Immunol 1985; 95: 46-53.
13. Eickelberg O, Roth M, Mussmann R, Rudiger JJ, Tamm M, Perruchoud AP, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999; 99: 2276-2282.
14. Matsumori A, Nunokawa Y, Sasayama S. Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci 2000; 67: 2655-2661.
15. Roitt IM, Brostoff J, Make D. Immunology. New York: Gower Medical Publishing, 1989.
16. Dong MK, Wilburn DJ, Conroy MC, Gilbertsen RB. Inhibition of interleukin-2 production and lymphocyte responsiveness by the cell activation inhibitor, CI-959. Agents Actions 1991; 34: 53-55.
17. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-dependent ion channels in T-lymphocytes. J Neuroimmunol 1985; 10: 71-95.
18. 2+ channels that is required for T cell activation. J Biol Chem 2008; 283: 12512-12519.
19. 2+ influx of U937 cells. FEBS Lett 1996; 394: 159-164.
20. Mason RP, Marche P, Hintze TH. Novel vascular biology of thirdgeneration L-type calcium channel antagonists: Ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23: 2155-2163.
21. Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999; 33: 242-249.
22. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
23. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol 2000; 131: 1521-1530.
24. Stepien O, Gogusev J, Zhu DL, Iouzalen L, Herembert T, Drueke TB, et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31: 786-793.
25. Chou TC, Li CY, Yen MH, Ding YA. Antiplatelet effect of amlodipine: A possible mechanism through a nitric oxide-mediated process. Biochem Pharmacol 1999; 58: 1657-1663.
26. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31: 275-281.
27. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
28. Gerondakis S, Grumont R, Rourke I, Grossmann M. The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol 1998; 10: 353-359.
29. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-88.
30. Nicholson ML, Dennis MJ, Beckingham IJ, Smith SJ. Effect of nifedipine on renal transplant rejection. Br J Surg 1993; 80: 1318-1321.
31. Suthanthiran M, Haschemeyer RH, Riggio RR, Adubor C, Friedman GS, Cheigh JS, et al. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation: A potential strategy to avoid antibody induction protocols. Transplantation 1993; 55: 1008-1013.
32. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
33. 2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. Biochem Biophys Res Commun 2004; 314: 695-703.
34. Petranka J, Wright G, Forbes RA, Murphy E. Elevated calcium in preneoplastic cells activates NF-kappa B and confers resistance to apoptosis. J Biol Chem 2001; 276: 37102-37108.
35. Jeremy JY, Barradas MA, Mikhailidis DP, Dandona P. Effects of verapamil and nisoldipine on human platelets: In vivo and in vitro studies. Br J Clin Pharmacol 1986; 22: 201-202.
36. Jeremy JY, Barradas MA, Mikhailidis DP, Dandona P. An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis. Drugs Exp Clin Res 1985; 11: 645-651.